Tuesday, September 14, 2021

Human Genetics 2021 - 2022 Seminar Series

3:00 PM to 4:00 PM

ZOOM MEETING ID: 947 5800 7294
PASSCODE: 900076
https://umich.zoom.us/j/94758007294?pwd=Sk9VMGlnTXRZWWJwbnZCZUx4MlI0QT09

Dr. Hayley McLoughlin is a Research Investigator in the University of Michigan department of Neurology. She earned her Neuroscience doctoral degree in 2013 from the University of Iowa in Dr. Bev Davidson's lab focusing on the role of small RNA biology in context of neural development and evolution. In 2014, she pursued a postdoctoral research fellowship under the guidance of Dr. Henry (Hank) Paulson at the University of Michigan, focused toward developing a gene therapy approach for Spinocerebellar Ataxia type 3/Machado-Joseph disease (SCA3/MJD). In 2016, she was appointed to Research Investigator in the Neurology department at the University of Michigan. She currently leads the ASO preclincial development for SCA3 disease through a collaboration with Ionis Pharmaceuticals, a world leader in antisense-oligonucleotide (ASO) therapies. Her research also focuses on exploring potent biomarkers and mechanisms of disease in both animal model and patient tissue samples for neurodegenerative diseases. Her work is currently funded through the NIH-NINDS CREATE Bio program, NIH-NINDS R21, and the National Ataxia Foundation.

Hayley McLoughlin, Ph.D. presents "Insights into SCA3 pathogenesis and gene silencing therapeutic development".

Hayley McLoughlin, Ph.D.
Research Assistant Professor
Department of Neurology
University of Michigan

Host:
Anthony Antonellis, Ph.D.
Chair, Department of Human Genetics
James V. Neel Collegiate Professor of Human Genetics
Professor of Neurology